Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.
Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Bria E, et al. Among authors: bonomi m. Crit Rev Oncol Hematol. 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Crit Rev Oncol Hematol. 2015. PMID: 25195095 Review.
Profiling mTOR pathway in neuroendocrine tumors.
Cingarlini S, Bonomi M, Corbo V, Scarpa A, Tortora G. Cingarlini S, et al. Among authors: bonomi m. Target Oncol. 2012 Sep;7(3):183-8. doi: 10.1007/s11523-012-0226-9. Epub 2012 Aug 14. Target Oncol. 2012. PMID: 22890559 Review.
Clinical meta-analyses of targeted therapies in adenocarcinoma.
Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. Bria E, et al. Among authors: bonomi m. Target Oncol. 2013 Mar;8(1):35-45. doi: 10.1007/s11523-013-0262-0. Epub 2013 Jan 25. Target Oncol. 2013. PMID: 23354875 Review.
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V, Vicentini C, Brunelli M, Nortilli R, Pellini F, Sperduti I, Giannarelli D, Pollini GP, Conte P, Tortora G. Bria E, et al. Among authors: bonomi m. Cancer Treat Rev. 2014 Aug;40(7):847-56. doi: 10.1016/j.ctrv.2014.05.001. Epub 2014 May 15. Cancer Treat Rev. 2014. PMID: 24877987
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Pinto C, et al. Among authors: bonomi m. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Rossi S, Finocchiaro G, Noia VD, Bonomi M, Cerchiaro E, Rose F, Franceschini D, Navarria P, Ceresoli GL, Beretta GD, D'Argento E, Scorsetti M, Santoro A, Toschi L. Rossi S, et al. Among authors: bonomi m. Future Oncol. 2019 Nov;15(33):3775-3782. doi: 10.2217/fon-2019-0349. Epub 2019 Nov 11. Future Oncol. 2019. PMID: 31709807
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P. Rayson D, et al. Among authors: bonomi m. Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26. Breast Cancer Res Treat. 2016. PMID: 27116183 Clinical Trial.
303 results